(Q47495783)

26 January 2022

CC(CC1=CC=CC=C1)N(C)CC#C

0 references

isomeric SMILES

C[C@H](CC1=CC=CC=C1)N(C)CC#C

1 reference

significant drug interaction

25 January 2018

1 reference

14 February 2018

1 reference

14 February 2018

1 reference

14 February 2018

propranolol

sinus bradycardia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

droperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

propranolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

levomepromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

levodopa

1 reference

A reference set of clinically relevant adverse drug-drug interactions

bupropion

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pethidine

toxicity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tramadol

toxicity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

moclobemide

hypertensive crisis

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

propranolol

orthostatic hypotension

1 reference

A reference set of clinically relevant adverse drug-drug interactions

toxic encephalopathy

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

muscle stiffness

1 reference

A reference set of clinically relevant adverse drug-drug interactions

seizure

1 reference

A reference set of clinically relevant adverse drug-drug interactions

palpitation

1 reference

A reference set of clinically relevant adverse drug-drug interactions

hypertensive crisis

1 reference

A reference set of clinically relevant adverse drug-drug interactions

headache disorder

1 reference

A reference set of clinically relevant adverse drug-drug interactions

levodopa

orthostatic hypotension

1 reference

A reference set of clinically relevant adverse drug-drug interactions

muscle stiffness

1 reference

A reference set of clinically relevant adverse drug-drug interactions

hypertensive crisis

1 reference

A reference set of clinically relevant adverse drug-drug interactions

palpitation

1 reference

A reference set of clinically relevant adverse drug-drug interactions

headache disorder

1 reference

A reference set of clinically relevant adverse drug-drug interactions

LiverTox likelihood score

LiverTox toxicity likelihood category E

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Selegiline

last update

21 July 2017

subject has role

monoamine oxidase inhibitor

1 reference

5 March 2018

C61938

1 reference

InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1

25 January 2018

0 references

Selegiline

0 references

Identifiers

InChI

1 reference

25 January 2018

2 references

25 January 2018

ChEBI release 2020-09-01

CAS Registry Number

14611-51-9

2 references

25 January 2018

https://commonchemistry.cas.org/detail?cas_rn=14611-51-9

9 April 2021

1 reference

25 January 2018

2 references

25 January 2018

Reaxys registry number

5863318

0 references

ChEBI ID

9086

mapping relation type

exact match

1 reference

International Chemical Identifier

InChI

InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1

ChEMBL ID

CHEMBL972

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

8 February 2021

2 references

inferred from InChIKey

MSBNK-Athens_Univ-AU211901

1 reference

MassBank accession ID

0 references

MSBNK-Athens_Univ-AU211902

0 references

MSBNK-Athens_Univ-AU211903

0 references

MSBNK-Athens_Univ-AU211904

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

splash10-00kr-0900000000-c3bb5ec6d20fa8013411

0 references

splash10-00kf-0900000000-e7203a719329bb43662b

0 references

splash10-014i-0900000000-5dd9d5d9fd58b17db25a

0 references

splash10-014u-3900000000-c1c87762e76f23d63f94

0 references

splash10-014u-6900000000-3bb9b58d7250c21fbe12

0 references

splash10-0006-9100000000-dc8e54056331eb04ea61

0 references

splash10-0006-9000000000-28c96bcb6b337cffa48f

0 references

splash10-0006-9000000000-2b84827991f2b204e24b

0 references

splash10-0006-9000000000-1a03d673c765f89794f2

0 references

splash10-0006-9000000000-372d3cd53616ca744247

0 references

splash10-00kf-9000000000-106d5900840da599fbd0

0 references

splash10-014i-9000000000-9ffe56a68f1c8b8e43a1

0 references

DSSTox substance ID

DTXSID6023575

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

0 references

ECHA Substance Infocard ID

100.109.269

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.109.269

retrieved

27 December 2018

title

Benzeneethanamine, N,.alpha.-dimethyl-N-2-propynyl-, (R)- (English)

quotation

CAS no.: 14611-51-9 (English)

Nikkaji ID

J34.132K

0 references

Guide to Pharmacology Ligand ID

6639

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

5 February 2021

1 reference

25 January 2018

1 reference

UNII

2K1V7GP655

2 references

UNII

2K1V7GP655

retrieved

25 January 2018